US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

HeartSciences Inc. - Common Stock (NQ:HSCS)

3.770 -0.590 (-13.53%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HeartSciences Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Fortitude Secures Priority Supply Allocation for BITMAIN’s Next-Generation Zcash Mining Equipment, Announces $100 Million Non-Binding Purchase Commitment, and Additional Upsizing of DCG Credit Facility and Available ZEC Funding from DCG
From Fortitude Mining Holdings, Inc.
Via Business Wire
News headline image
Fortitude Appoints Kimberly Pittman as Chief Legal Officer
From Fortitude Mining Holdings, Inc.
Via Business Wire
News headline image
Fortitude Announces Amendment to Existing DCG Credit Facility, Increasing Commitment by $24 Million and Providing for Future Funding in ZEC
From Fortitude Mining Holdings, Inc.
Via Business Wire
News headline image
Fortitude Appoints Jaime Leverton as Chief Executive Officer
From Fortitude Mining Holdings, Inc.
Via Business Wire
News headline image
HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Fortitude Provides Second Quarter 2026 Financial and Operating Highlights
From Fortitude Mining Holdings, Inc.
Via Business Wire
News headline image
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
Shares issued at $2.43, a 22% premium to the closing price on the purchase date, with Fortitude receiving no additional merger consideration in respect of the investment 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Fortitude Purchases 9,000 Bitmain Antminer Z15 Pro Units, Deepening Commitment to the Zcash Ecosystem
From Fortitude Mining Holdings, Inc.
Via Business Wire
News headline image
HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
Company believes proposed Fortitude merger represents a significant opportunity for the Company’s shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be... 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million. Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to... 
Via Benzinga
News headline image
Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets
From Fortitude Mining Holdings, Inc.
Via Business Wire
News headline image
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health’s FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences’... 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
Agreement follows Cibolo Health’s endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences’ ECG management platform 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Agreement with St. Vincent Health marks HeartSciences’ transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College... 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26)
Via ACCESS Newswire
News headline image
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire
BioMedNewsBreaks — HeartSciences Inc. (NASDAQ: HSCS; HSCSW) Secures UWE As Exclusive ECG Education Reference Center
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
Version 1.1 Designed to Provide Best Usability of any ECG System 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Inc (NASDAQ:HSCS) Reports Q1 FY2026 Results with Narrower-Than-Expected Loss and Positive Business Updates ↗
HeartSciences posts Q1 FY26 results with no revenue, a narrower-than-expected loss, and positive business updates including a key FDA designation and new software platform launch. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >